Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CPB2 | Q96IY4 | 4/20 | 0.41 |
| ▸ | CPB1 | P15086 | 3/20 | 0.41 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.36 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.36 |
| ▸ | F10 | P00742 | 5/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.33 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.33 |
| ▸ | CA12 | O43570 | 1/20 | 0.33 |
| ▸ | CA1 | P00915 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
| ▸ | CA9 | Q16790 | 1/20 | 0.33 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.33 |
| ▸ | MAOA | P21397 | 1/20 | 0.33 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.33 |
| ▸ | SYK | P43405 | 1/20 | 0.32 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.32 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL1277342 | 0.99 | CPB2 (0.41) | CPB2CPB1PDE3BPDE3AF10 | |
| SCHEMBL1277916 | 0.86 | PDE3B (0.49) | CPB2CPB1PDE3BPDE3AF10 | |
| SCHEMBL1699008 | 0.82 | F10 (0.37) | CPB2CPB1F10KLKB1 | |
| SCHEMBL28187390 | 0.80 | CPB2 (0.54) | CPB2CPB1PDE3BPDE3ANPC1 | |
| SCHEMBL3083099 | 0.78 | NPSR1 (0.40) | CPB2CPB1F10NOTUMCYP3A4 | |
| SCHEMBL1277718 | 0.77 | CPB1 (0.37) | CPB2CPB1F10KLKB1 | |
| SCHEMBL1993783 | 0.75 | ATM (0.36) | F10NPC1RAB9ANLRP3 | |
| SCHEMBL1698930 | 0.73 | CPB1 (0.39) | CPB2CPB1PDE3BPDE3ANPC1 | |
| SCHEMBL3094998 | 0.73 | F10 (0.52) | F10 | |
| SCHEMBL85901 | 0.73 | LOXL2 (0.43) | F10CA12CA1CA2CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8349873-B2 | Factor XA inhibitors | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2013-01-08 | — | — | US | disclosed |
| US-20120088795-A1 | FACTOR XA INHIBITORS | MILLENNIUM PHARMACEUTICALS, INC. | 2012-04-12 | — | — | US | disclosed |
| US-8063077-B2 | Factor Xa inhibitors | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2011-11-22 | — | — | US | disclosed |
| US-20110118244-A2 | FACTOR XA INHIBITORS | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2011-05-19 | — | — | US | disclosed |
| US-20100249117-A1 | FACTOR XA INHIBITORS | MILLENNIUM PHARMACEUTICALS, INC. | 2010-09-30 | — | — | US | disclosed |
| US-7767697-B2 | Factor Xa inhibitors | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2010-08-03 | — | — | US | disclosed |
| US-7763608-B2 | Factor Xa inhibitors | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2010-07-27 | — | — | US | disclosed |
| US-20090030045-A1 | FACTOR XA INHIBITORS | MILLENNIUM PHARMACEUTICALS, INC. | 2009-01-29 | — | — | US | disclosed |
| EP-2016072-A1 | FACTOR XA INHIBITORS | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2009-01-21 | — | — | EP | disclosed |
| WO-2007131179-A1 | FACTOR XA INHIBITORS | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2007-11-15 | — | — | WO | disclosed |
| US-20070259924-A1 | FACTOR XA INHIBITORS | MILLENNIUM PHARMACEUTICALS, INC. | 2007-11-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090030045-A1 | FACTOR XA INHIBITORS | TFPI, F12, F11 | CPB2 47/4885CPB1 36/4885PDE3B 154/4885 |
| US-20110118244-A2 | FACTOR XA INHIBITORS | TFPI, F12, F11 | CPB2 47/4885CPB1 36/4885PDE3B 154/4885 |
| US-20100249117-A1 | FACTOR XA INHIBITORS | TFPI, F12, F11 | CPB2 47/4885CPB1 36/4885PDE3B 154/4885 |
| US-20070259924-A1 | FACTOR XA INHIBITORS | TFPI, F12, F11 | CPB2 47/4885CPB1 36/4885PDE3B 154/4885 |
| US-20120088795-A1 | FACTOR XA INHIBITORS | TFPI, F12, F11 | CPB2 47/4885CPB1 36/4885PDE3B 154/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.